Clinical Trial Update: LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov update describes a Phase 1 study of combining Lutetium-177-PSMA-617 with Carboplatin in metastatic castration-resistant prostate cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING